Table 2

ORs of cardiometabolic risk factors comparing participants with iIFG or iIGT versus NGT

NGTiIFGiIGT
OR (95% CI)P valueOR (95% CI)P value
Central obesity1 (ref.)1.08 (0.23 to 5.13)0.9242.44 (0.71 to 8.35)0.156
BP≥130/85 mm Hg12.41 (0.86 to 6.76)0.0953.99 (1.46 to 10.93)0.007
TG≥1.7 mmol/L10.91 (0.28 to 3.00)0.8762.40 (0.95 to 6.07)0.065
HDL-C<1.04 mmol/L10.36 (0.05 to 2.97)0.3450.78 (0.20 to 3.05)0.721
HOMA-IR >3.013.50 (1.19 to 10.30)0.0233.65 (1.37 to 9.73)0.010
Metabolic syndrome11.36 (0.33 to 5.64)0.67432.60 (9.66 to 110.02)<0.001
NAFLD
 Mild12.17 (0.65 to 7.26)0.2081.10 (0.24 to 4.95)0.902
 Moderate to severe15.31 (0.71 to 39.41)0.1036.29 (1.04 to 37.86)0.045
  • Logistic regression models were used with adjustment for age, gender and body mass index.

  • P values in bold are significant at p<0.05.

  • BP, blood pressure; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment of insulin resistance; iIFG, isolated impaired fasting glucose; iIGT, isolated impaired glucose tolerance; NAFLD, non-alcoholic fatty liver disease; NGT, normal glucose tolerance; ref., reference; TG, triglyceride.